Oculis eye drop se­cures an­oth­er late-stage win, this time in post-cataract surgery in­flam­ma­tion and pain 

Oculis re­vealed an­oth­er win for its eye drops in a Phase III tri­al in post-cataract surgery in­flam­ma­tion and pain — af­ter tout­ing an ear­li­er late-stage study suc­cess back in May.

The Swiss biotech said the OP­TI­MIZE tri­al that stud­ied its once-dai­ly OCS-01 eye drops de­liv­ered sta­tis­ti­cal­ly sig­nif­i­cant im­prove­ments over a ve­hi­cle com­para­tor in in­flam­ma­tion and pain co­pri­ma­ry end­points.

Oculis CEO Ri­ad Sherif said on an in­vestor call Tues­day that the next step is to start an­oth­er Phase III tri­al to sup­port a po­ten­tial NDA sub­mis­sion. The ex­act tim­ing was not dis­closed. How­ev­er, Sharif said Oculis is work­ing on the sec­ond tri­al right now and plans to sub­mit an NDA by the end of next year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER